Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2016 May 22

PMID 27208380

Citations 447

Authors

Marta Guasch-Ferre

Adela Hruby

Estefania Toledo

Clary B Clish

Miguel A Martinez-Gonzalez

Jordi Salas-Salvado

Frank B Hu

Affiliations

Soon will be listed here.

Abstract

Objective: To conduct a systematic review of cross-sectional and prospective human studies evaluating metabolite markers identified using high-throughput metabolomics techniques on prediabetes and type 2 diabetes.

Research Design And Methods: We searched MEDLINE and EMBASE databases through August 2015. We conducted a qualitative review of cross-sectional and prospective studies. Additionally, meta-analyses of metabolite markers, with data estimates from at least three prospective studies, and type 2 diabetes risk were conducted, and multivariable-adjusted relative risks of type 2 diabetes were calculated per study-specific SD difference in a given metabolite.

Results: We identified 27 cross-sectional and 19 prospective publications reporting associations of metabolites and prediabetes and/or type 2 diabetes. Carbohydrate (glucose and fructose), lipid (phospholipids, sphingomyelins, and triglycerides), and amino acid (branched-chain amino acids, aromatic amino acids, glycine, and glutamine) metabolites were higher in individuals with type 2 diabetes compared with control subjects. Prospective studies provided evidence that blood concentrations of several metabolites, including hexoses, branched-chain amino acids, aromatic amino acids, phospholipids, and triglycerides, were associated with the incidence of prediabetes and type 2 diabetes. We meta-analyzed results from eight prospective studies that reported risk estimates for metabolites and type 2 diabetes, including 8,000 individuals of whom 1,940 had type 2 diabetes. We found 36% higher risk of type 2 diabetes per study-specific SD difference for isoleucine (pooled relative risk 1.36 [1.24-1.48]; I(2) = 9.5%), 36% for leucine (1.36 [1.17-1.58]; I(2) = 37.4%), 35% for valine (1.35 [1.19-1.53]; I(2) = 45.8%), 36% for tyrosine (1.36 [1.19-1.55]; I(2) = 51.6%), and 26% for phenylalanine (1.26 [1.10-1.44]; I(2) = 56%). Glycine and glutamine were inversely associated with type 2 diabetes risk (0.89 [0.81-0.96] and 0.85 [0.82-0.89], respectively; both I(2) = 0.0%).

Conclusions: In studies using high-throughput metabolomics, several blood amino acids appear to be consistently associated with the risk of developing type 2 diabetes.

Citing Articles

Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review.

Dhieb D, Mustafa D, Hassiba M, Alasmar M, Elsayed M, Musa A Biomedicines. 2025; 13(2).

PMID: 40002860 PMC: 11853021. DOI: 10.3390/biomedicines13020447.

Metabolomic Signatures in Adults with Metabolic Syndrome Indicate Preclinical Disruptions in Pathways Associated with High-Density Lipoprotein Cholesterol, Sugar Alcohols.

Lewis K, Stroebel B, Kanaya A, Aouizerat B, Longoria K, Flowers E Res Sq. 2025; .

PMID: 39989952 PMC: 11844646. DOI: 10.21203/rs.3.rs-5989567/v1.

A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults.

Ren Y, Chen B, Zhang H, Xu S Geroscience. 2025; .

PMID: 39904969 DOI: 10.1007/s11357-025-01544-6.

Proline exacerbates hepatic gluconeogenesis via paraspeckle-dependent mRNA retention.

Zhao Y, Chai X, Peng J, Zhu Y, Dong R, He J Nat Metab. 2025; 7(2):367-382.

PMID: 39820557 DOI: 10.1038/s42255-024-01206-5.

Multi-omics architecture of childhood obesity and metabolic dysfunction uncovers biological pathways and prenatal determinants.

Stratakis N, Anguita-Ruiz A, Fabbri L, Maitre L, Gonzalez J, Andrusaityte S Nat Commun. 2025; 16(1):654.

PMID: 39809770 PMC: 11732992. DOI: 10.1038/s41467-025-56013-7.

References

Drogan D, Dunn W, Lin W, Buijsse B, Schulze M, Langenberg C . Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes mellitus in a prospective, nested case control study. Clin Chem. 2014; 61(3):487-97. DOI: 10.1373/clinchem.2014.228965. View

Adams S, Hoppel C, Lok K, Zhao L, Wong S, Minkler P . Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr. 2009; 139(6):1073-81. PMC: 2714383. DOI: 10.3945/jn.108.103754. View

Zhou Y, Qiu L, Xiao Q, Wang Y, Meng X, Xu R . Obesity and diabetes related plasma amino acid alterations. Clin Biochem. 2013; 46(15):1447-52. DOI: 10.1016/j.clinbiochem.2013.05.045. View

Thalacker-Mercer A, Ingram K, Guo F, Ilkayeva O, Newgard C, Garvey W . BMI, RQ, diabetes, and sex affect the relationships between amino acids and clamp measures of insulin action in humans. Diabetes. 2013; 63(2):791-800. PMC: 3900549. DOI: 10.2337/db13-0396. View

Stancakova A, Civelek M, Saleem N, Soininen P, Kangas A, Cederberg H . Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes. 2012; 61(7):1895-902. PMC: 3379649. DOI: 10.2337/db11-1378. View

Fizelova M, Miilunpohja M, Kangas A, Soininen P, Kuusisto J, Ala-Korpela M . Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men. Atherosclerosis. 2015; 240(1):272-7. DOI: 10.1016/j.atherosclerosis.2015.03.034. View

Wurtz P, Soininen P, Kangas A, Ronnemaa T, Lehtimaki T, Kahonen M . Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2012; 36(3):648-55. PMC: 3579331. DOI: 10.2337/dc12-0895. View

Mahendran Y, Cederberg H, Vangipurapu J, Kangas A, Soininen P, Kuusisto J . Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. Diabetes Care. 2013; 36(11):3732-8. PMC: 3816902. DOI: 10.2337/dc13-0800. View

Ho J, Larson M, Vasan R, Ghorbani A, Cheng S, Rhee E . Metabolite profiles during oral glucose challenge. Diabetes. 2013; 62(8):2689-98. PMC: 3717862. DOI: 10.2337/db12-0754. View

10.

McGill J, Cole T, Nowatzke W, Houghton S, Ammirati E, Gautille T . Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care. 2004; 27(8):1859-65. DOI: 10.2337/diacare.27.8.1859. View

11.

Zhang A, Sun H, Yan G, Yuan Y, Han Y, Wang X . Metabolomics study of type 2 diabetes using ultra-performance LC-ESI/quadrupole-TOF high-definition MS coupled with pattern recognition methods. J Physiol Biochem. 2013; 70(1):117-28. DOI: 10.1007/s13105-013-0286-z. View

12.

Roberts L, Koulman A, Griffin J . Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. Lancet Diabetes Endocrinol. 2014; 2(1):65-75. DOI: 10.1016/S2213-8587(13)70143-8. View

13.

Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam K . Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes. 2012; 62(5):1730-7. PMC: 3636608. DOI: 10.2337/db12-0707. View

14.

Zhao J, Zhu Y, Hyun N, Zeng D, Uppal K, Tran V . Novel metabolic markers for the risk of diabetes development in American Indians. Diabetes Care. 2014; 38(2):220-7. PMC: 4302260. DOI: 10.2337/dc14-2033. View

15.

Yano M, Watanabe K, Yamamoto T, Ikeda K, Senokuchi T, Lu M . Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. J Biol Chem. 2010; 286(5):3992-4002. PMC: 3030399. DOI: 10.1074/jbc.M110.179176. View

16.

Xu F, Tavintharan S, Sum C, Woon K, Lim S, Ong C . Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics. J Clin Endocrinol Metab. 2013; 98(6):E1060-5. DOI: 10.1210/jc.2012-4132. View

17.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

18.

Li X, Xu Z, Lu X, Yang X, Yin P, Kong H . Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. Anal Chim Acta. 2009; 633(2):257-62. DOI: 10.1016/j.aca.2008.11.058. View

19.

Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, Gieger C . Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010; 5(11):e13953. PMC: 2978704. DOI: 10.1371/journal.pone.0013953. View

20.

Nicholson J, Lindon J . Systems biology: Metabonomics. Nature. 2008; 455(7216):1054-6. DOI: 10.1038/4551054a. View